Anaerobic Bacteria as Therapeutic Agents for Metastatic Cancer
Anaerobic Bacteria as Therapeutic Agents for Metastatic Cancer
批准号:
7229908
负责人:
Savio L Woo
金额:
$18.76万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2009-01-31
关键词:
Alcohol dehydrogenaseAnaerobic BacteriaAnimalsAppearanceAreaBacteriaBiodistributionBlood Chemical AnalysisBody WeightClinicalClostridium perfringensColon CarcinomaColorectalDevelopmentDigestive System DisordersDiseaseDisseminated Malignant NeoplasmDoseEnd PointExhibitsFacility Construction Funding CategoryFirefly LuciferasesFluorescenceFutureGene FamilyGenesGenetic RecombinationGenomicsGreen Fluorescent ProteinsGrowthHepatobiliaryHistologyHypoxiaImageImmuneIn VitroInflammatoryInvasiveKnock-outLaboratoriesLeadLesionLifeLiverLocalizedLuciferasesMalignant NeoplasmsMalignant neoplasm of pancreasMaximum Tolerated DoseModalityMonitorMusNecrosisNormal tissue morphologyNutritionalOrganOxidative StressOxygenPancreasPatientsPhospholipasePhospholipase CRateRecording of previous eventsReproduction sporesResearchResearch PersonnelResidual stateSerumSolid NeoplasmSpecificitySuperoxide DismutaseSystemTestingTherapeuticTherapeutic AgentsTimeToxic effectToxinTreatment Efficacybasecytokinegastrointestinalgene therapyglutathione peroxidaseimprovedinnovationintravenous administrationmetastatic colorectalmutantnovelnovel therapeuticsnutritionpancreatic neoplasmprogramsresponsetime usetranslational studytumorvectorwhole body imaging
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): As they grow in volume many tumors, including pancreatic and colon cancers, construct poorly vascularized and oxygen-deficient (hypoxic) areas that restrict the access by therapeutic agents and limit the efficacy of currently used anti-cancer modalities. However, the presence of hypoxia also offers the potential for anaerobic bacterial colonization that can lead to tumor destruction. One such anerobic bacterium is Clostridium perfringens (Cp), which contains a major toxin gene that encodes phospholipase C (plc). A plc-deleted strain of Cp (Cp/plc-) has been constructed in our laboratory and shown, after intravenous administration, to colonize and induce massive necrosis in solid tumors in mice. Unfortunately Cp/plc- retains some tolerance to oxygen that enables it to grow in normal tissues at a much reduced rate, and tumor-bearing mice treated with Cp/plc- at the effective doses also exhibited systemic toxicity. We hypothesize that Cp/plc- can be genetically modified to reduce substantially its oxygen tolerance, thereby creating sub-strains that will lead to tumor destruction without toxicity to normal tissues. We propose to delete the superoxide dismutase (sod) gene in a luciferase-expressing strain of Cp/plc-/LUC+ (Cp/plc-/sod-/LUC+). Immune- competent mice with pre-established syngeneic colorectal and pancreatic cancers in the liver will be treated by intravenous administration of Cp/plc-/sod-. Dose response curve and long-term survival at the maximal tolerated dose will be determined. Bacterial biodistribution and intratumoral growth will be determined as a function of time by repeated non-invasive whole-body imaging using luciferrin. Tumor responses in the treated animals will be evaluated by histological examination. Toxicity endpoints will include CBC, blood chemistries, serum proinflammatory cytokine levels and history of major organs. If necessary, additional oxygen tolerance genes can be deleted from Cp/plc-/sod- to further reduce toxicity. We hypothesize that these oxygen-intolerant mutant bacterial sub-strains can be safely applied in tumor-bearing animals, which will selectively localize to, germinate and grow in, and destroy tumors in hypoxic regions. Application of anaerobic bacterial-based vectors is a promising strategy for the development of an effective therapeutic agent that can be administered systemically to treat disseminated solid tumors with hypoxia, and may lead to clinical translational studies in patients with metastatic colorectal and/or pancreatic cancers in the future.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene.
产气荚膜梭菌的致癌效力与其α毒素基因无关。
DOI:
10.1089/hum.2008.145
发表时间:
2009
期刊:
Human gene therapy
影响因子:
4.2
作者:
[Li,Zhiyu, Fallon,John, Mandeli,John, Wetmur,James, Woo,SavioLC]
通讯作者:
Woo,SavioLC
A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.
一种用于胰腺癌肿瘤治疗的基因增强厌氧细菌。
DOI:
10.1093/jnci/djn308
发表时间:
2008
期刊:
Journal of the National Cancer Institute
影响因子:
--
作者:
[Li,Zhiyu, Fallon,John, Mandeli,John, Wetmur,James, Woo,SavioLC]
通讯作者:
Woo,SavioLC
Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer
-
批准号:7651591
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2009
-
负责人:Savio L Woo
-
依托单位:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
-
批准号:7077291
-
项目类别:
-
资助金额:$59.42万
-
财政年份:2006
-
负责人:Savio L Woo
-
依托单位:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
-
批准号:7667824
-
项目类别:
-
资助金额:$48.72万
-
财政年份:2006
-
负责人:Savio L Woo
-
依托单位:
Anaerobic Bacteria as Therapeutic Agents for Metastatic
-
批准号:7025161
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2006
-
负责人:Savio L Woo
-
依托单位:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
-
批准号:7476525
-
项目类别:
-
资助金额:$59.56万
-
财政年份:2006
-
负责人:Savio L Woo
-
依托单位:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
-
批准号:7929907
-
项目类别:
-
资助金额:$48.84万
-
财政年份:2006
-
负责人:Savio L Woo
-
依托单位:
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
-
批准号:7276134
-
项目类别:
-
资助金额:$59.22万
-
财政年份:2006
-
负责人:Savio L Woo
-
依托单位:
GROWTH, DIFFERENTIATION AND GENETIC ALTERATION OF HUMAN ES CELLS
-
批准号:7092813
-
项目类别:
-
资助金额:$5.56万
-
财政年份:2005
-
负责人:Savio L Woo
-
依托单位:
Genetic Reconstitution for Phenylketonuria
-
批准号:6680669
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Genetic Reconstitution for Phenylketonuria
-
批准号:6894830
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Oncolytic VSV for Hepatocellular Carcinoma
-
批准号:7810740
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Oncolytic VSV for Hepatocellular Carcinoma
-
批准号:8063653
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Genetic Reconstitution for Phenylketonuria
-
批准号:6765117
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Onoclytic VSV for Hepatocellular Carcinoma
-
批准号:7058803
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Oncolytic VSV for Hepatocellular Carcinoma
-
批准号:7431780
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Onoclytic VSV for Hepatocellular Carcinoma
-
批准号:6878618
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Onoclytic VSV for Hepatocellular Carcinoma
-
批准号:6747880
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Oncolytic VSV for Hepatocellular Carcinoma
-
批准号:7258999
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Oncolytic VSV for Hepatocellular Carcinoma
-
批准号:6605026
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
Oncolytic VSV for Hepatocellular Carcinoma
-
批准号:7618826
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2003
-
负责人:Savio L Woo
-
依托单位:
海外基金